Clinical value of metagenomic next-generation sequencing in patients with connective tissue diseases co-infections: a single-center study from southern hospital in China.

Publication date: Jun 20, 2025

This study aimed to assess the clinical value of metagenomic next-generation sequencing (mNGS) in patients with connective tissue diseases (CTDs) co-infections, thereby establishing a foundation for early infection identification and the development of anti-infective regimens. This retrospective study analyzed 304 CTD patients with suspected infections at the First Affiliated Hospital of Guangxi Medical University between October 2020 and April 2024. The study compared the diagnostic efficacy between mNGS and conventional microbiological testing (CMT), examined pathogen detection rates across different periods and pathogen types, and evaluated the clinical outcomes of mNGS-guided antimicrobial regimen adjustments. Among the 180 confirmed infections (Group I), mNGS demonstrated superior diagnostic performance compared to conventional microbiological testing (CMT). mNGS exhibited significantly higher sensitivity (89. 6% vs. 57. 0%; OR = 6. 5, 95% CI: 3. 7-11. 0, p 

Concepts Keywords
China Clinical value
Metagenomic Connective tissue diseases
Microbiological Infections
October Metagenomic next-generation sequencing
Rheumatol Pathogens

Semantics

Type Source Name
disease MESH co-infections
disease MESH connective tissue diseases
disease MESH infection
disease IDO pathogen

Original Article

(Visited 3 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *